Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of huntington's disease

Journal of Huntington's Disease

Volumn 3, Issue 4, 2014, Pages 333-341

  Miller, Silke ^a,e   Hill Della Puppa, Geraldine ^a   Reidling, Jack ^c   Marcora, Edoardo ^b   Thompson, Leslie M ^c,d  

^a AMGEN INC   (United States)

^b UCI Memory Impairments and Neurological Disorders Institute ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ADRX   (United States)

Author keywords

Basal Ganglia; degeneration; dopamine receptor; dopamine transporter; mouse model; Phosphodiesterase 10A; radioligand assay

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; RACLOPRIDE; TRACER; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR; PDE10A PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN ATROPHY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; ENZYME BINDING; EXON; GLOBUS PALLIDUS; HUNTINGTON CHOREA; LIGAND BINDING; MOUSE; NONHUMAN; SUBSTANTIA NIGRA; ANIMAL; BASAL GANGLION; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; FEMALE; INBRED MOUSE STRAIN; MALE; METABOLISM; RADIOASSAY;

ANIMALS; BASAL GANGLIA; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED STRAINS; PHOSPHORIC DIESTER HYDROLASES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE; SUBSTANTIA NIGRA;

EID: 84928694419     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140129     Document Type: Article

References (38)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-83.
2. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985;44:559-77.
3. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000;23:387-92.
4. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA. 2000;97:6763-68.
5. Rouaux C, Loeffler JP, Boutillier AL. Targeting CREBbinding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem Pharmacol. 2004;68:1157-64.
6. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999;274:18438-445.
7. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, Stephenson DT. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem. 2006;54:1205-13.
8. Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience. 2004;123:967-81.
9. Ahmad R, Bourgeois S, Postnov A, Schmidt ME, Bormans G, Van Laere K, Vandenberghe W. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology. 2014;82:279-81.
10. Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP, Marek KL. The phosphodiesterase 10 positron emission tomography tracer[18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol. 2014;71(12):1520-28.
11. Crook ZR, Housman D. Huntington's disease: Can mice lead the way to treatment? Neuron. 2011;69:423-35.
12. Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, MacDonald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A, Brunner D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis. 2009;35:319-36.
13. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493-506.
14. Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet. 2012;21:2219-32.
15. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28:6182-95.
16. Leuti A, Laurenti D, Giampa C, Montagna E, Dato C, Anzilotti S, Melone MA, Bernardi G, Fusco FR. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. Neurobiol Dis. 2013;52:104-116.
17. Ooms M, Rietjens R, Rangarajan JR, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernandez-Ruiz J, Bormans G, Van Laere K, Casteels C. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. Neurobiol Aging. 2014;35(12):2858-69.
18. Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One. 2010;5:e13417.
19. Hu E, Ma J, Biorn C, Lester-Zeiner D, Cho R, Rumfelt S, Kunz RK, Nixey T, Michelsen K, Miller S, Shi J, Wong J, Hill Della Puppa G, Able J, Talreja S, Hwang DR, Hitchcock SA, Porter A, Immke D, Allen JR, Treanor J, Chen H. Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer. J Med Chem. 2012;55:4776-87.
20. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, Pauli S, Sedvall G. PET study of the pre-and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain. 1997;120(Pt 3):503-14.
21. Turjanski N,Weeks R, Dolan R, Harding AE, Brooks DJ. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain. 1995;118(Pt 3):689-96.
22. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies, and National Research Council. Guide for the care and use of laboratory animals, 8th ed. Washington (DC): The National Academies Press; 2011.
23. Andres JI, De Angelis M, Alcazar J, Iturrino L, Langlois X, Dedeurwaerdere S, Lenaerts I, Vanhoof G, Celen S, Bormans G. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J Med Chem. 2011;54:5820-35.
24. Brandt J, Folstein SE, Wong DF, Links J, Dannals RF, McDonnell-Sill A, Starkstein S, Anders P, Strauss ME, Tune LE, et al. D2 receptors in Huntington's disease: Positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci. 1990;2:20-7.
25. Hagglund J, Aquilonius SM, Eckernas SA, Hartvig P, Lundquist H, Gullberg P, Langstrom B. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-Nmethyl-spiperone. Acta Neurol Scand. 1987;75:87-94.
26. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Disord. 1986;1:69-77.
27. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA. 1998;95:6480-85.
28. Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol. 2005;490:354-70.
29. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol. 2001;86: 2667-77.
30. Augood SJ, Faull RL, Emson PC. DopamineD1andD2receptor gene expression in the striatum in Huntington's disease. Ann Neurol. 1997;42:215-21.
31. Cha JH, Frey AS, Alsdorf SA,Kerner JA,Kosinski CM, Mangiarini L, Penney JB, Jr., Davies SW, Bates GP, Young AB. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci. 1999;354:981-89.
32. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology. J Neurosci. 1999;19:2522-34.
33. Filloux FM,Wamsley JK, Dawson TM. Dopamine D-2 autoand postsynaptic receptors in the nigrostriatal system of the rat brain: Localization by quantitative autoradiography with [3H]sulpiride. Eur J Pharmacol. 1987;138:61-8.
34. Filloux FM, Wamsley JK, Dawson TM. Presynaptic and postsynaptic D1 dopamine receptors in the nigrostriatal system of the rat brain: A quantitative autoradiographic study using the selective D1 antagonist [3H]SCH 23390. Brain Res. 1987;408:205-09.
35. Joyce JN, Marshall JF. Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: Localization to intrinsic neurons and not to neocortical afferents. Neuroscience. 1987;20:773-95.
36. Xie Z, AdamowiczWO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, Stephenson DT, Strick CA, Williams RD, Menniti FS. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience. 2006;139:597-607.
37. Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA, Richardson EP, Jr., Bird ED. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol. 1991;50:729-42.
38. van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, Veenma-van der Duin L, Pruim J, Roos RA, Leenders KL. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology. 2005;65: 941-3.